Peritumoral macrophages recruit eosinophils to promote antitumor immune responses in breast cancer

J Joseph Saglimbeni (Department of Pathology, New York University Grossman School of Medicine) E Eduardo Esteva (Department of Pathology, New York University Grossman School of Medicine) J Josue Canales (Department of Pathology, New York University Grossman School of Medicine) O Oriana A. Perez (Department of Pathology, New York University Grossman School of Medicine) A Anna Eichinger (Department of Pathology, New York University Grossman School of Medicine) W William Huntley (Department of Pathology, New York University Grossman School of Medicine) K Kamal M. Khanna I Igor Dolgalev (Applied Bioinformatics Laboratories, New York University Grossman School of Medicine) N Natalie Klar (Perlmutter Cancer Center, New York University Grossman School of Medicine) S Sylvia Adams (Perlmutter Cancer Center, New York University Grossman School of Medicine) B Boris Reizis

Abstract

Breast tumors harbor dynamic microenvironments, with multiple immune cell types playing opposing roles during tumor progression and/or response to therapy. Tumor-associated macrophages promote mammary tumorigenesis, whereas the role of mammary tissue macrophages (MTMs) remains incompletely understood. High-dimensional immunostaining of murine mammary tumor progression revealed that MTMs were localized in the peritumoral stroma and associated with eosinophils, which were previously shown to facilitate antitumor T cell responses. The depletion of MTMs accelerated tumorigenesis in both spontaneous and orthotopically transplanted mammary tumor models. Upon induction of a productive antitumor response via the depletion of regulatory T cells, MTMs assumed an alternatively activated state and expressed eotaxins, thereby attracting eosinophils to peritumoral regions. MTMs expressed the receptor for the alarmin IL-33, which induced both MTM activation and eosinophil recruitment. These results suggest that MTMs can sense IL-33 and recruit eosinophils to facilitate antitumor immunity, a mechanism that may operate during tumor progression and be further enhanced during productive antitumor responses.

Article Details

Volume / Issue Vol. 122, Issue 38
Published September 23, 2025
ISSN 0027-8424
Publisher National Academy of Sciences

Authors (11)

J

Joseph Saglimbeni

Department of Pathology, New York University Grossman School of Medicine

E

Eduardo Esteva

Department of Pathology, New York University Grossman School of Medicine

J

Josue Canales

Department of Pathology, New York University Grossman School of Medicine

O

Oriana A. Perez

Department of Pathology, New York University Grossman School of Medicine

A

Anna Eichinger

Department of Pathology, New York University Grossman School of Medicine

W

William Huntley

Department of Pathology, New York University Grossman School of Medicine

K

Kamal M. Khanna

I

Igor Dolgalev

Applied Bioinformatics Laboratories, New York University Grossman School of Medicine

N

Natalie Klar

Perlmutter Cancer Center, New York University Grossman School of Medicine

S

Sylvia Adams

Perlmutter Cancer Center, New York University Grossman School of Medicine

B

Boris Reizis